How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

677 results for

Sibutramine

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

261. Comparative Efficiency and Safety of Pharmacological Approaches to the Management of Obesity Full Text available with Trip Pro

7805975 0149-5992 0 Anti-Obesity Agents 0 Bridged Bicyclo Compounds, Heterocyclic 0 Cyclobutanes 0 Lactones 95M8R751W8 Orlistat BLH9UKX9V1 Tesofensine WV5EC51866 sibutramine IM Anti-Obesity Agents therapeutic use Bridged Bicyclo Compounds, Heterocyclic therapeutic use Cyclobutanes therapeutic use Humans Lactones therapeutic use Obesity drug therapy Orlistat 2011 4 29 6 0 2011 5 6 6 0 2011 7 2 6 0 ppublish 21525481 34/Supplement_2/S349 10.2337/dc11-s255 PMC3632205 Obesity (Silver Spring). 2009 Jan;17(1

2011 Diabetes Care

262. Obesity in adults Full Text available with Trip Pro

bypass, gastric banding, mazindol, orlistat (alone and in combination with sibutramine), phentermine, sibutramine (alone and in combination with orlistat), sleeve gastrectomy, and vertical banded gastroplasty.

2011 BMJ Clinical Evidence

263. Hepatic PTP1B expression involvement in the effects of Chinese medicine formula xiao-gao-jiang-zhuo using an obese rat model. (Abstract)

, the high-dose XGJZ group, the middle-dose XGJZ group, the low-dose XGJZ group, and the sibutramine group. After 14 weeks of treatment, body weight, abdominal fat, blood lipid and serum insulin level were measured, and the protein and gene expression of PTP1B in liver tissue was tested. Our data showed that the body weight of the high-dose and middle-dose groups and the sibutramine group had significant differences in comparison with the model group (p < 0.05), and all three dose groups had (...) significantly reduced abdominal fat (p < 0.05). The triglyceride level of the three dose groups and the sibutramine group, and the total cholesterol level of the middle-dose group were all significantly reduced (p < 0.05). The serum insulin of the high-dose and middle-dose groups also decreased significantly (p < 0.05). The expression of hepatic PTP1B mRNA of the three dose groups decreased significantly in comparison with the model group (p < 0.05 or 0.01). The expression of hepatic PTP1B protein

2011 American Journal of Chinese Medicine

264. Asthma Phenotypes in the Inner City

, nelfinavir); Calcium channel blockers (verapamil, diltiazem); Modafinil; Tamoxifen; non-nucleoside reverse transcriptase inhibitors; Macrolide antibiotics* (erythromycin, clarithromycin, dirithromycin, troleandomycin); chloramphenicol; nefazodone; aprepitant; St John's Wort; Rifampin*; Azole Antifungals* (ketoconazole, fluconazole, itraconazole); Sibutramine* ; bergamottin (constituent of grapefruit juice) (*may be rescreened if this therapy is short-lived); Should not be included in the study for any

2011 Clinical Trials

265. Tomato Consumption and High Density Lipoprotein-cholesterol

, estrogens or progesterone), metformin, other oral hypoglycemic agents, insulin, sibutramine, or orlistat treatment and those with daily consumption of any non-steroidal anti-inflammatory drug were also excluded. Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Please refer to this study by its ClinicalTrials.gov identifier (NCT

2011 Clinical Trials

266. Effects of Novel Fiber on Glucose Metabolism and Insulin Sensitivity

of medications or herbal remedies for weight loss (e.g., sibutramine, orlistat, amphetamines, phentermine, and ma huang) or use of these substances within the past 3 months Current or recent history (past 12 months) of drug, alcohol or chemical abuse. Alcohol abuse will be defined as >14 drinks per week (1 drink = 12 oz beer, 5 oz wine, or 1.5 oz hard liquor) Pregnant, breast-feeding or female of child-bearing potential who is unwilling to commit to the use of a medically approved form of contraception

2011 Clinical Trials

267. Safety and Efficacy of Exenatide Injection in Subjects With Type 2 Diabetes Mellitus

to participate and give written informed consent. Exclusion Criteria: Previous exposure to exenatide (anti-exenatide antibodies at screening) or a GLP-1 analogue. Used drugs for weight loss (for example, orlistat, sibutramine, phenylpropanolamine, rimonabant, or similar over-the-counter medications) within 3 months of screening. Received treatment within the last 30 days with a drug that has not received regulatory approval for any indication at the time of trial entry. Severe renal impairment (creatinine

2011 Clinical Trials

268. Effects of Anticholinergic or Long-Acting Beta 2 Agonist on FeNO and Pulmonary Function in SCI

; Phenylephrine; Pirbuterol; Propylhexedrine; Pseudoephedrine; Sibutramine; Terbutaline; Theophylline; Xylometazoline. Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01355991 Locations Layout table for location information United States, New Jersey Kessler

2011 Clinical Trials

269. Calcium Supplementation for a Healthy Weight (CaSHeW)

within the last six months of medications that can result in significant weight gain or weight loss, including antipsychotics, selective serotonin reuptake inhibitors, anti-epileptic drugs, appetite-suppressants such as phentermine and sibutramine, and the lipase-inhibitor orlistat. Active eating disorder History of alcoholism or substance abuse within 5 years prior to study entry. Use of a dietary supplement or medication that decreases calcium absorption History of kidney stone, hyperparathyroidism

2011 Clinical Trials

270. Changes of body weight and inflammatory markers after 12-week intervention trial: results of a double-blind, placebo-control pilot study. Full Text available with Trip Pro

Changes of body weight and inflammatory markers after 12-week intervention trial: results of a double-blind, placebo-control pilot study. Low grade inflammation is a well-known characteristic in obese subjects. We investigated body weight changes and inflammatory markers after 12-week intervention trial.Twenty-six obese subjects were enrolled and 19 (13 men and 6 women) completed the study. Sibutramine is an FDA-approved drug for body weight control; therefore, we chose this drug

2011 Yonsei medical journal Controlled trial quality: uncertain

271. Serotonin syndrome Full Text available with Trip Pro

effects, and is therefore not a dual action drug. Bupropion has also been suggested to cause serotonin syndrome, although as there is no evidence that it has any significant serotonergic activity, it is thought unlikely to produce the syndrome. In 2006 the United States issued an alert suggesting that the combined use of SSRIs or SNRIs and triptan medications or sibutramine could potentially lead to severe cases of serotonin syndrome. This has been disputed by other researchers as none of the cases

2012 Wikipedia

272. Management of obesity Full Text available with Trip Pro

, average weight loss on orlistat is 2.9 kg (6.4 lb), sibutramine is 4.2 kg (9.3 lb) and rimonabant is 4.7 kg (10 lb). Orlistat and rimonabant lead to a reduced incidence of diabetes, and all three drugs have some effect on . However, there is little information on how these drugs affect the longer-term complications or outcomes of obesity. In 2010 it was found that sibutramine increases the risk of and in people with a history of cardiovascular disease. There are a number of less commonly used (...) is not effective for inducing weight loss in the majority of people with obesity. It is being investigated to determine whether or not it helps with weight loss maintenance. The usefulness of certain drugs depends upon the comorbidities present. is preferred in overweight diabetics, as it may lead to mild weight loss in comparison to or . The , on the other hand, may cause weight gain, but decrease central obesity. Diabetics also achieve modest weight loss with , orlistat and sibutramine over 12–57 weeks

2012 Wikipedia

273. What are the current evidence based guidelines for GP's to prescribe orlistat? What are the current NICE guidelines for initiation and continuing to prescribe? How efficient is it? "

pressure) are present. Prescribing should be started and monitored only in specialist paediatric settings7. In children aged 12 years and older, treatment with orlistat or sibutramine is recommended only if physical comorbidities (such as orthopaedic problems or sleep apnoea) or severe psychological comorbidities are present. Treatment should be started in a specialist paediatric setting, by multidisciplinary teams with experience of prescribing in this age group. Orlistat or sibutramine should (...) be prescribed for obesity in children only by a multidisciplinary team with expertise in: • drug monitoring • psychological support • behavioural interventions • interventions to increase physical activity • interventions to improve diet. Orlistat and sibutramine should be prescribed for young people only if the prescriber is willing to submit data to the proposed national registry on the use of these drugs in young people (see section 4.5.3). After drug treatment has been started in specialist care, it may

2009 TRIP Answers

274. Planned CORR: Planned Care for Obesity and Risk Reduction

psychiatric disorder that would impair compliance with the study protocol (e.g. unstable depression, bipolar, schizophrenia). Is not pregnant or does not intend to become pregnant during the 2-year study period. Is not currently taking weight-altering medications (e.g. Sibutramine (Meridia), Orlistat (Xenical, Alli)), and has not taken them in at least 3 months. Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact

2010 Clinical Trials

275. Cholesterol Absorption Inhibition Study

antidepressants, narcotic analgesics, adrenergic agents, calcium channel blockers) Concomitant medication that can alter intestinal transit (e.g. loperamide, chemical/ osmotic/bulk laxatives), or influence satiety/energy intake (e.g. sibutramine, gluco¬corticoids, anabolic steroids) Intolerance or allergy for test product. Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact

2010 Clinical Trials

276. Effects of Exenatide on Glycemic Control and Weight in Continuous Subcutaneous Insulin Infusion (CSII) Type 2 Treated Patients With Type 2 Diabetes

lost (orlistat, sibutramine, rimonabant may be interrupted at least 3 months prior to inclusion in the study) Use of corticosteroid therapy for more than 10 days within the 3-past months, or patient who ought to be treated by corticosteroid during the study period Clinically significant hepatic disease Documented gastroparesis, or current use of drugs that directly affect gastrointestinal motility, or any significant abdominal disease that may increase the risk of adverse gastrointestinal effects

2010 Clinical Trials

277. Efficacy and Safety Study With Empagliflozin (BI 10773) vs. Placebo as add-on to Metformin or Metformin Plus Sulfonylurea Over 24 Weeks in Patients With Type 2 Diabetes

Contraindications to metformin and/or sulfonylurea according to the local label for those patients that enter the study with the respective background therapy Blood dyscrasias or any disorders causing haemolysis or unstable Red Blood Cell (e.g. malaria, babesiosis, haemolytic anaemia) Treatment with anti-obesity drugs (e.g. sibutramine, orlistat) 3 months prior to informed consent or any other treatment at the time of screening (i.e. surgery, aggressive diet regimen, etc.) leading to unstable body weight

2010 Clinical Trials

278. BI 10773 (Empagliflozin) Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME).

malabsorption Blood dyscrasias or any disorders causing haemolysis or unstable Red Blood Cell (e.g. malaria, babesiosis, haemolytic anemia) Medical history of cancer (except for basal cell carcinoma) and/or treatment for cancer within the last 5 years Contraindications to background therapy according to the local label Treatment with anti-obesity drugs (e.g. sibutramine, orlistat) 3 months prior to informed consent or any other treatment at the time of screening (i.e. surgery, aggressive diet regimen, etc

2010 Clinical Trials

279. Efficacy and Safety of Linagliptin (BI 1356) in Black/African Americans With Type 2 Diabetes With a MTT Sub-study

to the investigational product or its excipients. Treatment with insulin within 3 months prior to informed consent. Treatment with anti-obesity drugs (e.g., sibutramine, orlistat, rimonabant) within three months prior to informed consent or initiating therapy during the study. Any prior use of dipeptidyl peptidase-4 (DPP-4) inhibitors. Glucagon-like peptide-1 (GLP-1) agonists are excluded 3 months prior to informed consent. History of alcohol or drug abuse within 3 months prior to informed consent that would

2010 Clinical Trials

280. Empagliflozin (BI 10773) Dose Finder Study in Japanese Patients With Type 2 Diabetes Mellitus

with anti-obesity drugs (e.g. sibutramine, mazindol) 12 weeks prior to informed consent or any other treatment at the time of screening (i.e. surgery, aggressive diet regimen, etc.) leading to unstable body weight Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Please refer to this study by its ClinicalTrials.gov identifier (NCT

2010 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>